Phase 2 Start
IOBTQ: Phase 2 Start: An Open-Label Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced Hepatocellular Car
September 1, 2026 · wgi-0301. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- IO Biotech, Inc. (IOBTQ)
- Drug
- wgi-0301
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: An Open-Label Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced Hepatocellular Car
- Company
- IO Biotech, Inc. (IOBTQ)
- Drug
- wgi-0301
- Indication
- Advanced Hepatocellular Carcinoma (HCC)
Other upcoming events for IOBTQ
Phase 2 StartPhase 2 Start: 2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early A
Phase 2 StartPhase 2 Start: A Phase I/IIa, Randomized, Double Blind, Placebo Controlled, Dose Escalation and Cohort Expansion St
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit